AZ trumpets Farxiga survival data in renal disease at ESC 2020AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks Share XAZ trumpets Farxiga survival data in renal disease at ESC 2020https://pharmaphorum.com/news/az-trumpets-farxiga-survival-data-in-renal-disease-at-esc-2020/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
Trial shows AZ’s Farxiga slows onset of chronic kidney disease and cuts mortalityAstraZeneca’s Farxiga could be on course for another use, after trial results showed it slowed the worsening of Share XTrial shows AZ’s Farxiga slows onset of chronic kidney disease and cuts mortalityhttps://pharmaphorum.com/news/azs-farxiga-slows-onset-of-chronic-kidney-and-cuts-mortality/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
FDA approves AZ Imfinzi in new lung cancer useAstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, Share XFDA approves AZ Imfinzi in new lung cancer usehttps://pharmaphorum.com/news/fda-approves-az-imfinzi-in-new-lung-cancer-use/
FDA backs Glenmark’s rival to AZ’s blockbuster FarxigaAstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to Share XFDA backs Glenmark’s rival to AZ’s blockbuster Farxigahttps://pharmaphorum.com/news/fda-tentatively-backs-glenmarks-farxiga-generic/
